Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
IRVINE, Calif., Aug. 9, 2022 /PRNewswire/ — Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: www.clinicaltrials.gov/ct2/show/NCT05211986 The open label […]
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research. Sebastiano led development of the unique mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored […]
The Evolution of Stem Cell Therapy in the United States
Dr. Josh Crose summarizes the development and evolution of Stem Cell Therapy and the advent of Mesenchymal Stem Cell Extracellular Vesicles (Exosomes). Video Transcript: Hi, this is Dr Joshua Crose with Capitis Medical and Aesthetics. I’d like to talk about stem cell therapies and provide you a little bit of a background in summary about […]
RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
EDINBURGH, UK AND HOPKINTON, MA, 4 August 2022 – RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience (‘Lykan’), an innovative CDMO focused on cell-based therapies, today announce that they have entered into a business combination agreement to form a global leading innovative […]
Global Mesenchymal Stem Cells Market Intelligence Report 2022: Industry to reach $5.84 Billion by 2027
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) — The “Mesenchymal Stem Cells Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Mesenchymal Stem Cells Market is projected to reach USD 5,847.88 million by 2027 from USD 2,731.51 million in 2021, at a CAGR 13.52% during the forecast period. […]
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates. Through the alliance, TransCode and MD […]
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
NEW YORK, Aug. 1, 2022 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern […]
Why Are Stem Cells The Future Of Medicine
Why do stem cells matter for the future of medicine? NYSCF’s Senior Vice President of Research Scott Noggle, PhD dives into the basics of stem cell research and what it means for diseases like Alzheimer’s, macular degeneration, and ALS. Watch Dr. Noggle’s full presentation here.
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study
PHOENIX, July 28, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company’s OvaStem® pilot study. The data shows significant efficacy of […]
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) — The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and efficacy of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid, for the treatment of non-healing venous stasis ulcers. The Research […]